Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Habitrol Nicotine Patch Three-Year Exclusivity Sought By Novartis

This article was originally published in The Tan Sheet

Executive Summary

A shortened duration of use and a new, essential clinical investigation supporting OTC use of the Habitrol transdermal nicotine patch merits the granting of three years of marketing exclusivity, Novartis Consumer Health maintains.

You may also be interested in...



Habitrol

CHPA urges FDA to grant marketing exclusivity to Novartis Consumer Health for transdermal nicotine patch. In comments submitted to agency Dec. 7, CHPA says "it is vital for FDA to maintain a regulatory environment conducive to the appropriate switch of drugs from prescription to OTC use." Trade group reiterates Novartis' claim that shortened duration of use and new, essential clinical investigation entitles company to three-year marketing exclusivity (1"The Tan Sheet" Nov. 6, p. 11). FDA is reviewing its initial exclusivity denial

Habitrol

CHPA urges FDA to grant marketing exclusivity to Novartis Consumer Health for transdermal nicotine patch. In comments submitted to agency Dec. 7, CHPA says "it is vital for FDA to maintain a regulatory environment conducive to the appropriate switch of drugs from prescription to OTC use." Trade group reiterates Novartis' claim that shortened duration of use and new, essential clinical investigation entitles company to three-year marketing exclusivity (1"The Tan Sheet" Nov. 6, p. 11). FDA is reviewing its initial exclusivity denial

Habitrol

CHPA urges FDA to grant marketing exclusivity to Novartis Consumer Health for transdermal nicotine patch. In comments submitted to agency Dec. 7, CHPA says "it is vital for FDA to maintain a regulatory environment conducive to the appropriate switch of drugs from prescription to OTC use." Trade group reiterates Novartis' claim that shortened duration of use and new, essential clinical investigation entitles company to three-year marketing exclusivity (1"The Tan Sheet" Nov. 6, p. 11). FDA is reviewing its initial exclusivity denial

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS091854

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel